Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.
Our own Kui Wang will share initial #data from the collaboration between @CasebiaTx and @Bayer to increase #geneediting efficiency and improve LNP stability as a poster at #ASGCT19. You can view the full abstract at https://t.co/0R73cE7H8w
Alan Brooks from @CasebiaTx will be giving an oral presentation on our research around liver targeted insertion with LNP/AAV during #ASGCT19 to highlight our findings to date and the potential to treat #hemophiliaA in the future. Read more at https://t.co/hvAYXSU8Zo